Sign In
Buy KNSA
$60.94
-2.50 (-3.94%)
At Close: Jul 13, 2026
Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why
09:56am, Monday, 06'th Jul 2026
Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the sever
What Makes Kiniksa Pharmaceuticals International, plc (KNSA) a Strong Momentum Stock: Buy Now?
01:01pm, Tuesday, 30'th Jun 2026
Does Kiniksa Pharmaceuticals International, plc (KNSA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Kiniksa Pharmaceuticals International, plc (KNSA) Surges 5.4%: Is This an Indication of Further Gains?
09:01am, Tuesday, 30'th Jun 2026
Kiniksa Pharmaceuticals International, plc (KNSA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue
Grab These 4 Stocks With Solid Net Profit Margins to Maximize Returns
09:21am, Monday, 29'th Jun 2026
Let's take a look at four stocks, BTSG, KNSA, ATI and VMI, with stellar net profit margins and rising EPS estimates that can help create a winning portfolio.
Here's Why You Should Add Kiniksa Stock to Your Portfolio Now
11:35am, Friday, 26'th Jun 2026
KNSA's Arcalyst sales continue to grow as raised 2026 revenue guidance and an expanding IL-1 pipeline reinforce Kiniksa's growth strategy.
Is Kiniksa Pharmaceuticals International PLC (KNSA) Overvalued After 3.5% Rally? GF Value Says Overvalued
08:48pm, Monday, 22'nd Jun 2026
On June 22, 2026, Kiniksa Pharmaceuticals International PLC (KNSA) shares rose 3.5% today, bringing the current price to $57.13. The stock has shown strong perf
Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going
09:56am, Friday, 19'th Jun 2026
If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice. It is one of the several stocks that
New Strong Buy Stocks for June 18th
06:06am, Thursday, 18'th Jun 2026
TWFG, XPO, MUSA, FLYW and KNSA have been added to the Zacks Rank #1 (Strong Buy) List on June 18, 2026.
Kiniksa Pharmaceuticals International, plc (KNSA) Upgraded to Strong Buy: Here's What You Should Know
01:02pm, Tuesday, 16'th Jun 2026
Kiniksa Pharmaceuticals International, plc (KNSA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Kiniksa Pharmaceuticals International, plc (KNSA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
01:22am, Wednesday, 10'th Jun 2026
Kiniksa Pharmaceuticals International, plc (KNSA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
A Look at Kiniksa Pharmaceuticals International PLC (KNSA) After 4.8% Decline -- GF Value $46.92 vs Price $48.41
06:36pm, Friday, 29'th May 2026
On May 29, 2026, Kiniksa Pharmaceuticals International PLC (KNSA) shares fell 4.8% to $48.41, reflecting a downward trend in the stock's performance over the pa
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
04:01pm, Friday, 29'th May 2026
LONDON, May 29, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in fireside chats at the following investor confere
Kiniksa: Increased Outlook For Arcalyst, Augmented By Pipeline Maturation
11:10am, Wednesday, 29'th Apr 2026
Kiniksa Pharmaceuticals continues to outperform, with Arcalyst net sales poised to surpass my previous bullish estimates. Arcalyst captured 18% of the recurrent pericarditis market by end-2025, with a
Breakfast News: Enphase Dips As Solar Demand Dims
07:30am, Wednesday, 29'th Apr 2026
Enphase suffers from weaker U.S. demand, Fiverr jumps on Q1 earnings beat, and more
Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today
07:10pm, Tuesday, 28'th Apr 2026
Its Arcalyst has been on the market for years, yet it posted strong sales growth in the period. More is to come, apparently, as management raised its net sales guidance for the drug.
